


Data Sheet

Product Name:	NX-13
Cat. No.:	CS-0179403
CAS No.:	2389235-01-0
Molecular Formula:	C ₂₄ H ₂₁ N ₃ O ₃
Molecular Weight:	399.44
Target:	NOD-like Receptor (NLR)
Pathway:	Immunology/Inflammation
Solubility:	DMSO : 135 mg/mL (337.97 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the **NLRX1** pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis^{[1][2]}. IC50 & Target: NLRX1^[1] **In Vivo:** NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels^[2].

NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract^[2].

References:

[1]. Leber A, et.al. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1 [published online ahead of print, 2019 Oct 25]. Drug Chem Toxicol. 2019;1-6.

[2]. Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203(12):3407-3415.

CAIndexNames:

Pyridine, 2,2',2''-[1,3,5-benzenetriyltris(oxy)]tris[6-methyl-

SMILES:

CC1=NC(OC2=CC(OC3=CC=CC(C)=N3)=CC(OC4=CC=CC(C)=N4)=C2)=CC=C1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA